Mode
Text Size
Log in / Sign up

Meta-analysis of adjunctive therapies for recurrent rhinosinusitis shows improved outcomes with conventional treatment.

Meta-analysis of adjunctive therapies for recurrent rhinosinusitis shows improved outcomes with conv…
Photo by CDC / Unsplash
Key Takeaway
Consider integrating adjunctive therapies into standard protocols for a multimodal approach to recurrent rhinosinusitis management.

This meta-analysis examined the efficacy of adjunctive therapies, such as nasal irrigation, physiotherapy, steroid-eluting implants, and dental interventions, when combined with standard rhinosinusitis treatment. The study included 1,608 patients and compared these multimodal approaches against conventional treatment alone to assess clinical and radiological outcomes.

Key synthesized findings demonstrated a 30–50% improvement in symptom scores measured by SNOT-22 and RSDI, with 95% confidence intervals provided. Recurrence rates showed a significant reduction, and post-operative success rates for steroid-eluting implants and concurrent dental interventions exceeded 90%. Additionally, mucociliary clearance was reported as improved across the pooled data.

The authors acknowledge that heterogeneity was moderate, with an I2 value less than 50%. Safety profiles, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the source data. Consequently, the certainty of these clinical benefits is tempered by the lack of safety information and the observational nature of the pooled evidence regarding specific interventions.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundRecurrent and chronic rhinosinusitis remain challenging conditions with high recurrence rates despite advances in medical and surgical management. Adjunctive therapies ranging from nasal irrigation and physiotherapy to steroid-eluting implants and dental interventions are increasingly used to enhance treatment outcomes. This meta-analysis aimed to evaluate the effectiveness of adjunctive therapies in improving clinical and radiological outcomes in patients with recurrent rhinosinusitis.MethodsA comprehensive literature search was conducted across PubMed, Scopus, ScienceDirect, Google Scholar, and the Consensus Academic Database for studies published between 2015 and 2025. Eligible studies included randomized controlled trials and observational research evaluating adjunctive therapies combined with standard rhinosinusitis treatment. Data extraction and quality assessment followed PRISMA 2020 guidelines using the Cochrane Risk of Bias Tool (RoB 2) and Newcastle Ottawa Scale. Quantitative and qualitative syntheses were performed, with effect sizes expressed as mean differences and 95% confidence intervals.ResultsNine studies comprising a total of 1,608 patients were included. Adjunctive therapies demonstrated a 30–50% improvement in symptom scores (SNOT-22, RSDI) and a significant reduction in recurrence rates compared to conventional treatment alone. Higher improvement rates were reported in studies evaluating steroid-eluting implants and concurrent dental interventions, which achieved over 90% post-operative success rates. Non-surgical modalities such as nasal irrigation and sinus physiotherapy also yielded meaningful symptomatic relief and improved mucociliary clearance. Heterogeneity was moderate (I2 < 50%), and no significant publication bias was detected in the funnel plot analysis.ConclusionAdjunctive therapies significantly improve symptom control, reduce recurrence, and enhance post-operative outcomes in recurrent rhinosinusitis. Integrating these modalities into standard treatment protocols supports a multimodal, patient-centered approach to disease management. Future multicentric randomized controlled trials with standardized intervention protocols are recommended to confirm and refine these findings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.